Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 17/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23795925 | 1.00 | HDAC4 (0.53) | HDAC4HDAC6HDAC1NPC1RAB9A | |
| SCHEMBL23795923 | 1.00 | HDAC4 (0.53) | HDAC4HDAC6HDAC1NPC1RAB9A | |
| SCHEMBL28633355 | 0.90 | LMNA (0.48) | HDAC4NPC1RAB9ALMNA | |
| SCHEMBL28633357 | 0.90 | LMNA (0.48) | HDAC4NPC1RAB9ALMNA | |
| SCHEMBL23796332 | 0.90 | HDAC6 (0.52) | HDAC4HDAC6NPC1RAB9ALMNA | |
| SCHEMBL23796142 | 0.90 | HDAC6 (0.52) | HDAC4HDAC6NPC1RAB9ALMNA | |
| SCHEMBL23796144 | 0.90 | HDAC6 (0.52) | HDAC4HDAC6NPC1RAB9ALMNA | |
| SCHEMBL23796081 | 0.88 | NPC1 (0.45) | HDAC4HDAC6NPC1RAB9ALMNA | |
| SCHEMBL23796204 | 0.88 | NPC1 (0.45) | HDAC4HDAC6NPC1RAB9ALMNA | |
| SCHEMBL23796082 | 0.88 | NPC1 (0.45) | HDAC4HDAC6NPC1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11866431-B2 | Bicyclic compounds | VIVACE THERAPEUTICS, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| US-20230061429-A1 | BICYCLIC COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| EP-3877356-A1 | BICYCLIC COMPOUNDS | Vivace Therapeutics, Inc. (US) | 2021-09-15 | — | — | EP | disclosed |
| CN-113302175-A | Bicyclic compounds | 维瓦斯治疗公司 | 2021-08-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11866431-B2 | Bicyclic compounds | YAP1, MYC, TEAD2 | HDAC4 625/4885HDAC6 276/4885HDAC1 124/4885 |
| US-20230061429-A1 | BICYCLIC COMPOUNDS | YAP1, MYC, TEAD2 | HDAC4 625/4885HDAC6 276/4885HDAC1 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.